Lenvatinib Mesilate Capsules：

Indications：

This product is indicated for patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Patients with hepatocellular carcinoma amenable to locoregional therapy were excluded from the pivotal study of lenvatinib mesylate, and thus no study data are available for these patients.